APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1/2 Unknown 51 enrolled Ascentage Pharma Group Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-1252 single agent and in combination with other therapeutic agent in patients with NHL.

Timeline

Start: 2022-06-14
Primary completion: 2025-09
Completion: 2026-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pelcitoclax	Small molecule	—	Intravenous
Subject	Tucidinostat	Small molecule	30 mg	Oral

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Summary

Timeline

Drugs

Indications